Trelagliptin
| CAS No. | 865759-25-7 | Cat. No. | BCP10450 |
| Name | Trelagliptin | ||
| Synonyms | SYR472; SYR-472; SYR 472; | ||
| Formula | C18H20FN5O2 | M. Wt | 357.38 |
| Description | Trelagliptin, also known as SYR-472, is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed by Takeda for the treatment of type 2 diabetes (T2D). Once-weekly SYR-472 treatment produced clinically and statistically significant improvements in glycaemic control in patients with type 2 diabetes. It was well tolerated and might be a new treatment option for patients with this disease. Trelagliptin (Zafatek(®)) was approved in Japan for the treatment of type 2 diabetes mellitus (T2DM). | ||
| Pathways | Protease/Metabolic Enzyme | ||
| Targets | DPP | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.